Trial reportThe Lancet. Respiratory medicine2016
Pilot evaluation of ivacaftor for chronic bronchitis.
Abstract readLetterRandomized Controlled Trial
In one paragraph
Trial report in The Lancet. Respiratory medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2025Trial
- Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.International journal of chronic obstructive pulmonary disease · 2020Trial
- Uncovering sodium overload-associated gene signatures in chronic obstructive pulmonary disease through integrated bioinformatics and machine learning.Journal of thoracic disease · 2026Article
- Therapeutic strategies to reverse cigarette smoke-induced ion channel and mucociliary dysfunction in COPD airway epithelial cells.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Multi-modal transcriptomic analysis reveals metabolic dysregulation and immune responses in chronic obstructive pulmonary disease.Scientific reports · 2024Article
- Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Article
- Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?International journal of molecular sciences · 2023Review
- Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages.Scientific reports · 2023Article
- Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities.Drugs & aging · 2023Review
- Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.The European respiratory journal · 2023Review
- Extracellular Vesicles' Role in the Pathophysiology and as Biomarkers in Cystic Fibrosis and COPD.International journal of molecular sciences · 2022Review
- Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.The European respiratory journal · 2022Article
- Therapeutic CFTR Correction Normalizes Systemic and Lung-Specific S1P Level Alterations Associated with Heart Failure.International journal of molecular sciences · 2022Article
- Cystic fibrosis transmembrane regulator correction attenuates heart failure-induced lung inflammation.Frontiers in immunology · 2022Article
- The molecular evolution of function in the CFTR chloride channel.The Journal of general physiology · 2021Article
- Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine.Biomedicines · 2021Review
- Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.Scientific reports · 2021Article
- Cerebral Autoregulation in Subarachnoid Hemorrhage.Frontiers in neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
George M SolomonDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
Heather HathorneDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
Bo LiuDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
S Vamsee RajuDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
Ginger ReevesDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
Edward P AcostaDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
Mark T DransfieldDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
Steven M RoweDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Cell Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA. Electronic address: smrowe@uab.edu.
Funding
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MUAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4MUAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Brian R. Davis · 2007 to 2026
$23.0MUAB CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE (CCTS) UL1: BPCAUL1RR025777 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUAY-WOODFORD, LISA MARIE · 2008 to 2011
$22.3MMolecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPDR01HL105487 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2011 to 2016
$2.7MA Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-TOPIC)R34HL127166 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DRANSFIELD, MARK T, ROWE, STEVEN MARK · 2015 to 2016
$600kNCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001417NCRR NIH HHS UL1 RR025777NHLBI NIH HHS R01 HL105487NHLBI NIH HHS R34 HL127166NIDDK NIH HHS P30 DK072482
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAminophenolsBronchitis, ChronicChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMolecular Targeted TherapyPilot ProjectsPulmonary Disease, Chronic ObstructiveQuinolonesRisk AssessmentAminophenolsChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorivacaftorQuinolones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.